Isomorphic Labs raises $5 billion for AI drug discovery
Demis Hassabis' startup secured a massive Series C funding round to use artificial intelligence to design and develop new medicines.
The short version
- Isomorphic Labs raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital.
- Alphabet, Google's parent company, also participated in the investment round.
- The company aims to use AI to model biology at the molecular level to accelerate medicine development.
- Drug discovery startups raised a record $23.2 billion in 2026, according to Dealroom.
Why it matters
This investment signals a massive shift toward using AI to solve complex biological problems rather than just generating text. For patients, it could mean faster timelines for moving new treatments from the lab into clinical trials.
A massive capital injection
Isomorphic Labs announced on Tuesday that it has secured $5 billion in a Series C funding round. This significant amount of capital is intended to fuel the design and development of new medicines using artificial intelligence. The round was co-led by the venture capital firms Greenoaks and Sequoia Capital.
Other major players joined the investment, including Andreessen Horowitz. Notably, Alphabet, the parent company of Google, also provided funding. This influx of cash follows a previous Series B round in May, which brought in $2.1 billion for the company.
The timing of this funding is particularly notable given the leadership changes at Google DeepMind. It comes just three-and-a-half months after Demis Hassabis stepped back from his role as the CEO of DeepMind, the AI lab he co-founded before Google acquired it in 2014.
The goal of molecular modeling
Isomorphic Labs was spun out of DeepMind in 2021 with a specific focus on biology. The company is building a proprietary drug design engine that uses AI to identify therapeutic candidates. The goal is to understand and model biology at the most fundamental molecular level.
By creating foundational biology models, the company hopes to deepen the understanding of systemic diseases. This approach is designed to move beyond traditional methods of drug discovery, which can often be slow and unpredictable. The company intends to use these models to drive its first therapeutic programs toward clinical trials.
Hassabis stated that the company's conviction is that biology can be radically accelerated through AI. He noted that this new funding will help the company deliver a tangible impact for patients by speeding up the path to new treatments. The focus remains on creating the next generation of medicines through high-tech modeling.
A booming market for AI drugs
The investment in Isomorphic Labs is part of a much larger trend in the biotech industry. Drug discovery startups have seen record funding poured into them in 2026. According to the deal-counting platform Dealroom, these startups raised a total of $23.2 billion this year.
Investors are increasingly looking to capitalize on the rapid advances in artificial intelligence. They see AI as a tool that can navigate the complexities of human biology more efficiently than manual research alone. This interest has led to a surge in capital flowing toward companies that combine biology with machine learning.
Other major technology players are also entering this space to compete. For example, Anthropic announced a new AI drug discovery program in June. Additionally, OpenAI entered into a partnership with Novo Nordisk in April to develop medicines using similar technology.
Impact on the pharmaceutical landscape
The rise of AI-driven drug discovery changes how pharmaceutical companies might approach new treatments. Instead of testing thousands of compounds blindly, researchers can use AI to narrow down the most promising candidates. This could significantly reduce the time and cost associated with bringing a new drug to market.
For the broader industry, the involvement of heavyweights like Alphabet and Sequoia Capital suggests that AI is becoming a core pillar of biotechnology. It moves the needle from AI being a novelty to AI being a primary tool for scientific discovery. This shift affects how research labs are structured and how they prioritize their targets.
As Isomorphic Labs moves toward clinical trials, the industry will be watching to see if these AI-designed drugs perform as expected. If successful, it could set a new standard for how all future medicines are discovered and validated. The success of these programs will determine how much the pharmaceutical world relies on these new models.
What comes next for Isomorphic
With $5 billion in new capital, Isomorphic Labs is positioned to expand its pipeline of therapeutic candidates. The company will likely focus on building out its proprietary engine to handle more complex disease models. This involves moving from theoretical biology models to practical applications in human health.
The company's next major milestone will be the transition of its AI-generated candidates into clinical trials. These trials are the necessary steps to prove that a drug is safe and effective for human use. This is where the
Sources and links
- ReportingCNBC: the article we sourced
First reported by CNBC. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.